Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing
(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.
In our opinion, there’s no more egregious biotech investment where investors are ignoring all the warning signs than Intra-Cellular Therapies, Inc. (“ITCI”) and its lead compound ITI-007, originally billed as a sleep-aid but currently under development to treat schizophrenia. We’ve found negative data being hidden from investors, a drug sold by a savvy big-pharma to ITCI for a pittance, questionable trial metrics and pharmacodynamic properties for the lead compound that call into question whether or not this drug will ever find widespread adoption if it even works at all.
Click below to download the full copy of the Little Bear Investments July 15th 2015 Research Report on Intra-Cellular, Inc. :
To give you a taste, below is one of the proprietary pieces of data included in this report. It shows just how questionable ITI-007 really is:
Disclosure : At the time of publication of this report, Little Bear and its’ affiliates hold short positions in Intra-Cellular Therapies, Inc. common stock.